National Institute for Health and Care Excellence

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

There is a simple discount patient access scheme for teplizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess ...
National Institute for Health and Care Excellence

Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy

There is a simple discount patient access scheme for cemiplimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

Evidence-based recommendation on teplizumab (Tzield) for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes ...
The National Institute for Health and Care Excellence

Novel life-saving liver procedure recommended, potentially enabling hundreds more transplants

It’s the first time a NICE committee has reviewed the evidence behind the procedure which preserves the donor liver by pumping oxygenated blood through it using a machine for around two hours. This ...
The National Institute for Health and Care Excellence

New technologies could help cut years-long wait for endometriosis diagnosis

Endometriosis affects around 1 in 10 women of reproductive age in the UK, yet the average time to diagnosis is more than 9 ...
National Institute for Health and Care Excellence

Browse guidance by topic

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...
The National Institute for Health and Care Excellence

New draft PMOS guideline recommends annual review and could mean quicker diagnosis

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...
National Institute for Health and Care Excellence

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a commercial access agreement for daratumumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact jnj_imukcs@its.jnj.com ...
National Institute for Health and Care Excellence

NICE guidance

Evidence-based recommendations for the health and social care sector, developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
National Institute for Health and Care Excellence

Drug misuse

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
National Institute for Health and Care Excellence

Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

they are having triple therapy including an inhaled corticosteroid (ICS), a long-acting beta-2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), and the company provides mepolizumab ...
National Institute for Health and Care Excellence

Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer

Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults. This guidance updates and replaces NICE technology ...